Bioxodes SA
7.7 FTEThe score of Bioxodes shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets -14 % Headcount (avg FTE) -12 %
Accounts of the company itself (not consolidated).
The full file covers 15 financial years; a free account shows 2. →Bioxodes's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 02 Jul 2026
- Year ended 31 Dec 2024filed on 16 Jul 2025
- Year ended 31 Dec 2023filed on 23 Jul 2024
- Year ended 31 Dec 2022filed on 14 Jul 2023
- Year ended 31 Dec 2021filed on 23 Aug 2022
Bioxodes's financial analysis
- Solvency-21.6%sector median: 57.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Bioxodes
Bioxodes's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0825.151.779
- VAT number
- BE0825151779
- Peppol
- Registered · 0208:0825151779 · as of 25 Oct 2026
- Legal form
- SA
- Incorporated
- 20 Apr 2010
- Registered office
- 6041 Charleroi
- Size
- Micro · 7.7 FTE
- Latest accounts
- 2025 · filed on 02 Jul 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Bioxodes (SA) has been based in Charleroi since 2010, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of €3.44m and equity of −€1.66m; its revenue is not published. With 7.7 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at -21.6%, below the median of its sector (57.9%).
Companies similar to Bioxodes
Companies in the same business, of comparable size and area, outside its group.
- Amyl Therapeutics Research and experimental development on natural sciences and engineering Liège · balance sheet €7.02m
- Intrexon Actobiotics Research and experimental development on natural sciences and engineering Nazareth-De Pinte · balance sheet €8.76m
- BIO-Sourcing Research and experimental development on natural sciences and engineering Liège · balance sheet €6.59m
- ImmunXperts Research and experimental development on natural sciences and engineering Charleroi · balance sheet €9.58m
- AstriVax Therapeutics Research and experimental development on natural sciences and engineering Leuven · balance sheet €12.5m
- Tanai Therapeutics Research and experimental development on natural sciences and engineering Ghent · balance sheet €3.87m
- ExeVir Bio Research and experimental development on natural sciences and engineering Ghent · balance sheet €3.76m
- Genflow Biosciences Research and experimental development on natural sciences and engineering Charleroi · balance sheet €3.74m
Frequently asked questions about Bioxodes
What is the revenue of Bioxodes?
Bioxodes files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Bioxodes?
In Belgium, the VAT number is the company number prefixed with BE: BE0825151779 for Bioxodes, if the company is VAT-registered. Its company number (CBE) is 0825.151.779.
Where is the registered office of Bioxodes?
According to the CBE register, the registered office of Bioxodes is in 6041 Charleroi.
What is the equity of Bioxodes?
At the close of the 2025 financial year, the equity of Bioxodes amounts to -1,662,624 €, a solvency of -21.6% of total assets.
How many people work at Bioxodes?
7.7 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Bioxodes?
The register lists 11 active mandates at Bioxodes. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Bioxodes
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →